Page last updated: 2024-12-10

daphnetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5280569
CHEMBL ID244948
CHEBI ID17313
SCHEMBL ID128212
MeSH IDM0119233

Synonyms (92)

Synonym
EU-0000106
BRD-K61269089-001-01-4
nsc-633563
7,8-dihydroxy-2h-chromen-2-one
CHEBI:17313 ,
daphnetol
7,8-dihydroxy-2h-1-benzopyran-2-one
DIVK1C_006960
einecs 207-632-8
coumarin, 7,8-dihydroxy-
brn 0009372
2h-1-benzopyran-2-one, 7,8-dihydroxy-
nsc 633563
EU-0100330
7,8-dihydroxycoumarin, >=97%, powder
NCGC00015349-01
lopac-d-5564
7,8-dihydroxychromen-2-one
nsc633563
7,8-dihydroxy-coumarin
BSPBIO_002488
OPREA1_044324
LOPAC0_000330
HSCI1_000053
C03093
7,8-dihydroxycoumarin ,
486-35-1
daphnetin ,
inchi=1/c9h6o4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12
7,8-dihydroxycoumarin, 90%
KBIO1_001904
KBIO3_001708
KBIOGR_001808
SPECTRUM3_000784
SPECPLUS_000864
SPECTRUM4_001254
NCGC00093770-02
NCGC00093770-01
NCGC00015349-02
D 5564
NCGC00015349-05
AKOS000277449
smr001230713
MLS002153288
CHEMBL244948 ,
TCMDC-125839 ,
bdbm50206006
AE-641/02519040
HMS3261A21
D4001
A827573
CCG-39736
NCGC00015349-04
NCGC00015349-03
unii-xc84571rd2
5-18-03-00211 (beilstein handbook reference)
xc84571rd2 ,
FT-0603132
NCGC00015349-06
LP00330
PB17055
S2554
daphnetin [mi]
daphnetin [inci]
MLS006012039
SCHEMBL128212
7,8-dihydroxy-2h-benzopyran-2-one
NCGC00261015-01
tox21_500330
1,8-dihydroxycoumarin
ATEFPOUAMCWAQS-UHFFFAOYSA-N
7,8-dihydroxy-2h-chromen-2-one #
7,8-dihydroxy-chromen-2-one
Q-100543
HB0229
mfcd00016977
DTXSID00197560
HMS3656G16
AS-63138
sr-01000075820
SR-01000075820-2
SR-01000075820-1
SW000346-2
CS-0008778
HY-N0281
Q27102315
STL558976
BRD-K61269089-001-02-2
BBL036425
SDCCGSBI-0050318.P003
NCGC00015349-12
EN300-7424503

Research Excerpts

Overview

Daphnetin (Daph) is a natural coumarin derivative that exerts anti-oxidative and anti-inflammatory properties. It has been previously demonstrated to ameliorate DSS-induced ulcerative colitis (UC)

ExcerptReferenceRelevance
"Daphnetin is a dehydroxylated derivative of coumarin isolated from Daphne species. "( Daphnetin inhibits α-MSH-induced melanogenesis via PKA and ERK signaling pathways in B16F10 melanoma cells.
An, SK; Bae, S; Lee, JH; Nam, G; Park, IC, 2022
)
3.61
"Daphnetin (Daph) is a coumarin obtained from the plant genus Daphne species that exerts anti-oxidative and anti-inflammatory properties."( Up-regulation of Nrf2/HO-1 and inhibition of TGF-β1/Smad2/3 signaling axis by daphnetin alleviates transverse aortic constriction-induced cardiac remodeling in mice.
Kulhari, U; Kumar, A; Kundu, S; Mohapatra, P; Mugale, MN; Murty, US; Ram, C; Sahu, BD; Syed, AM, 2022
)
1.67
"Daphnetin (DAP) is a coumarin derivative that has various bioactivities."( Daphnetin Mitigates Ovalbumin-Induced Allergic Rhinitis in Mice by Regulating Nrf2/HO-1 and TLR4/NF-kB Signaling.
Jiang, R; Ma, X; Tian, B, 2023
)
3.07
"Daphnetin is a natural product with anti-inflammatory, antioxidant, and neuroprotective properties. "( Daphnetin alleviates neuropathic pain in chronic constrictive injury rats
Cui, S; Liang, W; Ou, W; Zhang, M; Zhang, S; Zhang, T, 2023
)
3.8
"Daphnetin is a natural coumarin compound with anti-inflammatory, anti-oxidant, and anti-apoptotic effects, which has been previously demonstrated to ameliorate DSS-induced ulcerative colitis (UC). "( Daphnetin attenuates intestinal inflammation, oxidative stress, and apoptosis in ulcerative colitis via inhibiting REG3A-dependent JAK2/STAT3 signaling pathway.
He, Z; Liu, J; Liu, Y, 2023
)
3.8
"Daphnetin (Daph) is a natural compound with a variety of biological activities."( Daphnetin ameliorates PM2.5-induced airway inflammation by inhibiting NLRP3 inflammasome-mediated pyroptosis in CS-exposed mice.
Ci, X; Fan, X; Gao, Y; Hua, C; Peng, L, 2023
)
3.07
"Daphnetin (DAP) is a traditional Chinese drug usually used to treat cardiovascular diseases. "( Chondroprotective and antiarthritic effects of Daphnetin used in vitro and in vivo osteoarthritis models.
Huang, X; Li, J; Luan, Z; Wei, Q; Wu, Z; Yang, Z; Yao, J; Zhang, X; Zou, K, 2020
)
2.26
"Daphnetin is a 7, 8 dihydroxy coumarin widely distributed in Thymelaeaceae family plants, possessing various activities such as anti-arthritic, anti-tumor, anti-malarial, and anti-parasitic."( Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Bhatti, R; Kaur, A; Singh, AP; Singh, L, 2021
)
2.79
"Daphnetin (Daph) is a natural coumarin derivative that is clinically used to treat rheumatoid arthritis and coagulopathy and exhibits antioxidant effects."( Daphnetin ameliorated GM-induced renal injury through the suppression of oxidative stress and apoptosis in mice.
Ci, X; Fan, C; Fan, X; Gao, Y; Gu, W; Ma, N, 2021
)
2.79
"Daphnetin is a 7, 8 dihydroxy coumarin isolated from different medicinal plants of the Thymelaeaceae family and exhibits copious pharmacological activities including neuroprotection, anti-cancer, anti-malarial, anti-inflammatory, anti-parasitic and anti-arthritic activity. "( Mechanistic interplay of various mediators involved in mediating the neuroprotective effect of daphnetin.
Bhatti, R; Singh, AP; Singh, L, 2021
)
2.28
"Daphnetin (DAPH) is a natural coumarin derivative with anti-inflammation, anti-microorganism and anti-oxidative properties."( Daphnetin prevents methicillin-resistant Staphylococcus aureus infection by inducing autophagic response.
Cheng, C; Ge, W; He, L; Lu, Y; Shang, W; Shi, L; Wu, Q; Zhang, W; Zhu, B; Zhuo, S, 2019
)
2.68
"Daphnetin is a dihydroxycoumarin that is being used in China for the treatment of coagulation disorders. "( Daphnetin: a novel antimalarial agent with in vitro and in vivo activity.
Lin, XB; Meshnick, SR; Pan, HZ; Ranz, A; Yang, YZ; Zhang, ZN, 1992
)
3.17

Effects

Daphnetin has been developed as an oral medicine for treatment of coagulation disorders and rheumatoid arthritis in China. Its in vitro metabolism remains unknown, but it has anti-hemolytic and anti-erythrocytic lipid peroxidation effects.

ExcerptReferenceRelevance
"Daphnetin (DAP) has been studied for its anti-inflammatory and antiangiogenic properties with encouraging results."( Daphnetin inhibits corneal inflammation and neovascularization on a mouse model of corneal alkali burn.
Guo, L; Liu, G; Meng, C; Wang, X; Yang, T; Zheng, F; Zheng, Y, 2022
)
2.89
"Daphnetin has confirmed anti-inflammatory effects against various diseases."( Daphnetin exerts an anticancer effect by attenuating the pro-inflammatory cytokines.
Hu, P; Li, H; Liu, R; Pei, Q; Yang, T; Zhang, H, 2021
)
2.79
"Daphnetin (Daph) has been reported to exhibit various pharmacological activities, particularly its antiinflammatory property."( Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-κB, and the induction of autophagy.
Ci, X; Fan, X; Feng, H; Lv, H; Wang, L, 2018
)
2.64
"Daphnetin has been shown to alleviate organ injury in a variety of preclinical animal models of coagulation disorders."( Protective effects of daphnetin on sodium taurocholate‑induced severe acute pancreatitis in rats.
Liu, J; Liu, TY; Liu, ZY; Shi, Q; Wang, LK; Wang, WX; Zhao, KL; Zhao, L; Zuo, T, 2014
)
1.44
"Daphnetin has been developed as an oral medicine for treatment of coagulation disorders and rheumatoid arthritis in China, but its in vitro metabolism remains unknown. "( Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin.
Fang, ZZ; Ge, GB; Li, GH; Li, W; Liang, SC; Liu, HX; Wang, LM; Wu, JJ; Yang, L; Yin, L; Zhang, JW; Zhang, YY, 2010
)
2.01
"Daphnetin has anti-hemolytic and anti-erythrocytic membranous lipid peroxidation effects."( [Anti-hemolytic and anti-membranous lipid peroxidation effects of daphnetin].
Liu, Y; Ni, Y; Wang, M; Xu, Y, 1999
)
1.98
"Daphnetin has been shown to be a potent in vitro anti-proliferative agent to the human renal cell carcinoma (RCC) cell line, A-498. "( Daphnetin induced differentiation of human renal carcinoma cells and its mediation by p38 mitogen-activated protein kinase.
Creaven, BS; Egan, DA; Finn, GJ, 2004
)
3.21

Actions

Daphnetin displays certain schizontocidal activity both in vitro and in vivo. It was found to suppress the growth of P. and can suppress the renal, urine parameters.

ExcerptReferenceRelevance
"Daphnetin considerably suppress the renal, urine parameters."( Nephro-protective effect of Daphnetin in hyperoxaluria-induced rat renal injury via alterations of the gut microbiota.
Gong, X; Wen, W; Zhang, W; Zhao, Y; Zhou, R, 2022
)
1.74
"Daphnetin displays certain schizontocidal activity both in vitro and in vivo."( The schizontocidal activity of daphnetin against malaria parasites in vitro and in vivo.
Cai, Y; Ha, SH; Ni, YC; Wang, QM; Xu, YQ, 2000
)
2.04
"Daphnetin was found to suppress the growth of P."( Iron chelator daphnetin against Pneumocystis carinii in vitro.
Wu, WH; Ye, B; Zhang, J; Zheng, YQ, 2004
)
1.41
"Daphnetin can suppress the growth of P. "( Iron chelator daphnetin against Pneumocystis carinii in vitro.
Wu, WH; Ye, B; Zhang, J; Zheng, YQ, 2004
)
2.13

Treatment

Daphnetin treatment considerably altered the microbial composition of different bacteria at phylum, genus and family level. The drug attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in mice.

ExcerptReferenceRelevance
"Daphnetin treatment considerably altered the microbial composition of different bacteria at phylum, genus and family level."( Nephro-protective effect of Daphnetin in hyperoxaluria-induced rat renal injury via alterations of the gut microbiota.
Gong, X; Wen, W; Zhang, W; Zhao, Y; Zhou, R, 2022
)
1.74
"Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice."( Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice.
Chen, F; Fang, H; Gao, J; Mi, J; Qi, Q; Yang, M, 2020
)
2.72
"Daphnetin pretreatment attenuated the behavioral and biochemical changes induced by reserpine."( Daphnetin, a natural coumarin averts reserpine-induced fibromyalgia in mice: modulation of MAO-A.
Bhatti, R; Kaur, A; Singh, AP; Singh, L, 2021
)
2.79
"Daphnetin-treated rats showed upregulation of body weight compared to other groups."( Daphnetin exerts an anticancer effect by attenuating the pro-inflammatory cytokines.
Hu, P; Li, H; Liu, R; Pei, Q; Yang, T; Zhang, H, 2021
)
2.79
"Daphnetin pretreatment significantly reduced SAP-induced pancreatic and lung tissue damage, reduced interleukin-6 and tumour necrosis factor-α concentrations in both serum and lung tissues, reduced serum amylase and myeloperoxidase activities, and reduced macrophage (CD11b) and neutrophil (Ly6G) infiltration and cell apoptosis in the lung tissue."( Daphnetin ameliorates acute lung injury in mice with severe acute pancreatitis by inhibiting the JAK2-STAT3 pathway.
Bi, X; Chen, S; Duan, X; Geng, Y; Liu, Y; Song, Y; Wang, Q; Wu, Z; Yang, S; Zhang, Y; Zhu, C, 2021
)
2.79
"Daphnetin treatment reduced the levels of serum alanine transaminase and creatinine (CR), increased superoxide dismutase(SOD) activity, and decreased neutrophil infiltration and cell apoptosis of the pancreatic tissues in rat SAP."( Role of Daphnetin in Rat Severe Acute Pancreatitis Through the Regulation of TLR4/NF-[Formula: see text]B Signaling Pathway Activation.
Liu, J; Liu, Z; Shi, Q; Wang, G; Wang, W; Zhao, K; Zuo, T, 2016
)
1.59
"Daphnetin treatment also reduced the levels of Th1/Th2/Th17 type cytokines in spleen lymphocytes in CIA rats."( The therapeutic effects of daphnetin in collagen-induced arthritis involve its regulation of Th17 cells.
Fu, Y; Kuang, N; Li, S; Tu, L; Yang, S; Yao, R; Zeng, X; Zhang, Z, 2012
)
1.4

Toxicity

ExcerptReferenceRelevance
" Based on the obtained data, and the conditions of the experiments, we can conclude that the 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin is a safe molecule up to a concentration of 10 μg/ml, which encourages further studies aiming to explore its potential as a drug candidate."( Cytogenotoxicity assessment of 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin on HepG2/C3A cells and leukocytes.
Almeida-Terassi, LM; Castanha, APM; Guardado-Yordi, E; Maistro, EL; Matos, MJ, 2023
)
0.91

Pharmacokinetics

Daphne giraldii extract can reduce the t(1/2), tmax and Ke of daphnetin, while increased the Ka and AUC(0-infinity) Comparing with oral administration of CD extract, AUC and Tmax of dAPHnetin significantly increased after giving CD-GU (p<0.0).

ExcerptReferenceRelevance
"Glycyrrhiza extract can reduce the t(1/2), tmax and Ke of daphnetin, while increased the Ka and AUC(0-infinity)."( [Effects of glycyrrhiza extract on pharmacokinetics property of daphnetin in rats].
Cai, B; Chen, L; Di, L; Liu, H; Shan, J; Zhao, X; Zhou, W, 2011
)
0.85
" In order to clarify the rationality of herbaceous compatibility between CD and GU, the comparative evaluations on pharmacokinetic behaviors of daphnetin (a predominantly active ingredient in CD) after intragastric administration of CD and CD-GU (combination of CD and GU) extract were studied."( The effects of Glycyrrhizae uralenis and its major bioactive components on pharmacokinetics of daphnetin in Cortex daphnes in rats.
Chen, LT; Di, LQ; Kang, A; Li, JS; Qian, S; Shan, JJ; Zhang, W, 2014
)
0.82
"Comparing with oral administration of CD extract, AUC and Tmax of daphnetin significantly increased after giving CD-GU (p<0."( The effects of Glycyrrhizae uralenis and its major bioactive components on pharmacokinetics of daphnetin in Cortex daphnes in rats.
Chen, LT; Di, LQ; Kang, A; Li, JS; Qian, S; Shan, JJ; Zhang, W, 2014
)
0.86
"To establish HPLC-MS/MS method for simultaneous determination of daphnetin, daphnoretin, and daphneticin in rat plasma after oral and intravenous administration of Daphne giraldii extract, and then use them in the calculation of pharmacokinetic parameters."( [Simultaneous determination of daphnetin, daphnoretin, daphneticin in rat plasma by LC-MS/MS and its application in pharmacokinetic study].
Cao, SL; Dong, XX; Fu, J; Hu, YY; Lin, LF; Ni, J; Yang, CJ; Zhang, M, 2017
)
0.98

Compound-Compound Interactions

ExcerptReferenceRelevance
"The aim of the present study was to investigate the effects of daphnetin combined with B cell lymphoma 2 (Bcl2)‑targeted small interfering (si)RNA (si‑Bcl2) on antiapoptotic genes in fibroblast‑like synoviocytes (FLS) in rats with collagen II‑induced arthritis (CIA)."( Effects of daphnetin combined with Bcl2‑siRNA on antiapoptotic genes in synovial fibroblasts of rats with collagen‑induced arthritis.
Chen, X; Fu, Y; Kuang, N; Li, Y; Liu, W; Zeng, X; Zhang, Z, 2018
)
1.11

Bioavailability

ExcerptReferenceRelevance
"In this study, it was found that liquiritin, one of the major components of GU, significantly enhanced the bioavailability of the main component daphnetin in CD."( The effects of Glycyrrhizae uralenis and its major bioactive components on pharmacokinetics of daphnetin in Cortex daphnes in rats.
Chen, LT; Di, LQ; Kang, A; Li, JS; Qian, S; Shan, JJ; Zhang, W, 2014
)
0.82
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxycoumarinAny coumarin carrying at least one hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
daphnin interconversion010
daphnetin modification111
daphnetin modification115

Protein Targets (71)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency15.18610.003245.467312,589.2998AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency35.48130.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency9.97630.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency20.81140.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency20.81140.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency7.07950.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency22.38720.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency37.68580.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency25.11890.012610.691788.5700AID887
ATAD5 protein, partialHomo sapiens (human)Potency6.51040.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency1.77830.35487.935539.8107AID624146
Microtubule-associated protein tauHomo sapiens (human)Potency33.99720.180013.557439.8107AID1460; AID1468
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency18.88760.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency15.82640.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.26580.001530.607315,848.9004AID1224819; AID1224820; AID1224821
GVesicular stomatitis virusPotency10.68400.01238.964839.8107AID1645842
pyruvate kinaseLeishmania mexicana mexicanaPotency15.84890.398113.744731.6228AID945; AID959
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.86750.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency32.34040.016525.307841.3999AID504836; AID602332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency53.581823.934123.934123.9341AID1967
D(1A) dopamine receptorHomo sapiens (human)Potency1.03220.02245.944922.3872AID488982
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency14.12540.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency50.11870.006026.168889.1251AID488953
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency2.81840.010039.53711,122.0200AID1479
DNA polymerase betaHomo sapiens (human)Potency14.12540.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency8.49270.133725.412989.1251AID488816; AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency21.33130.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency22.38720.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency23.77810.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency23.10930.004611.374133.4983AID504364
DNA polymerase kappa isoform 1Homo sapiens (human)Potency9.46620.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency50.31260.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency22.38720.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency25.11890.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency25.11890.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency7.94330.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency10.68400.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency7.94330.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.68400.01238.964839.8107AID1645842
phosphoglycerate kinaseTrypanosoma brucei brucei TREU927Potency13.45910.07578.474229.0628AID504547
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency7.56860.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)7.67000.00000.536910.0000AID325539
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)140.00000.00021.557410.0000AID403341
Xanthine dehydrogenase/oxidaseHomo sapiens (human)IC50 (µMol)390.00000.00132.81389.8200AID294445
Autoinducer 2-binding periplasmic protein LuxPVibrio harveyiIC50 (µMol)12.00002.00003.00004.0000AID314588
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)IC50 (µMol)11.77000.00442.923510.0000AID1701173
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Ki1.75000.00101.46539.5400AID1701173
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (200)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
allantoin metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of protein phosphorylationXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell proliferationXanthine dehydrogenase/oxidaseHomo sapiens (human)
guanine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
inosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyinosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
adenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyadenosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
deoxyguanosine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
AMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
IMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
lactationXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of gene expressionXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron-sulfur cluster assemblyXanthine dehydrogenase/oxidaseHomo sapiens (human)
amide catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of endothelial cell differentiationXanthine dehydrogenase/oxidaseHomo sapiens (human)
GMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dGMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
dAMP catabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of p38MAPK cascadeXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayXanthine dehydrogenase/oxidaseHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processXanthine dehydrogenase/oxidaseHomo sapiens (human)
negative regulation of vasculogenesisXanthine dehydrogenase/oxidaseHomo sapiens (human)
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (66)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
xanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
iron ion bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein homodimerization activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine dehydrogenase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
hypoxanthine oxidase activityXanthine dehydrogenase/oxidaseHomo sapiens (human)
FAD bindingXanthine dehydrogenase/oxidaseHomo sapiens (human)
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (50)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
peroxisomeXanthine dehydrogenase/oxidaseHomo sapiens (human)
cytosolXanthine dehydrogenase/oxidaseHomo sapiens (human)
sarcoplasmic reticulumXanthine dehydrogenase/oxidaseHomo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (147)

Assay IDTitleYearJournalArticle
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224752Delta TM value showing the stabilisation of CAMK2B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224749Delta TM value showing the stabilisation of CAMK1D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224786Delta TM value showing the stabilisation of PIM1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID615280Inhibition of quorum sensing regulated bioluminescence in Vibrio harveyi2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Medicinal chemistry as a conduit for the modulation of quorum sensing.
AID1224799Delta TM value showing the stabilisation of NDR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806Delta TM value showing the stabilisation of VRK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224776Delta TM value showing the stabilisation of ERK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224789Delta TM value showing the stabilisation of PLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325540Inhibition of PKA2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224785Delta TM value showing the stabilisation of PDK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224807Delta TM value showing the stabilisation of YSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224784Delta TM value showing the stabilisation of PCTK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224801Delta TM value showing the stabilisation of MST1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224772Delta TM value showing the stabilisation of MAP2K6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224757Delta TM value showing the stabilisation of CDK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224774Delta TM value showing the stabilisation of p38beta produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224764Delta TM value showing the stabilisation of CK1G1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224763Delta TM value showing the stabilisation of CLK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1326317Antimicrobial activity against vancomycin-resistant Enterococcus faecalis after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1224790Delta TM value showing the stabilisation of PLK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224791Delta TM value showing the stabilisation of PRKACA produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224783Delta TM value showing the stabilisation of PAK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224766Delta TM value showing the stabilisation of CK1G3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224777Delta TM value showing the stabilisation of MST4(1) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1326318Antimicrobial activity against vancomycin-sensitive Enterococcus faecalis after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1326311Inhibition of Escherichia coli FtsZ polymerization expressed in Escherichia coli BL21 assessed as reduction in light scattering intensity in presence of GTP by fluorescence spectrometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1224780Delta TM value showing the stabilisation of OSR1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1701173Displacement of FAM-Bid peptide from recombinant N-terminal His6x-tagged human Mcl-1 expressed in Escherichia coli BL21 (DE3) incubated for 30 mins by fluorescence polarization assay2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
AID1244054Antiproliferative activity against human U937 cells after 3 days2015European journal of medicinal chemistry, Aug-28, Volume: 101Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1224770Delta TM value showing the stabilisation of JAK1~B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1349248Antioxidant activity assessed as DPPH radical scavenging activity incubated for 30 mins under dark condition2017Journal of natural products, 12-22, Volume: 80, Issue:12
Regioselective IBX-Mediated Synthesis of Coumarin Derivatives with Antioxidant and Anti-influenza Activities.
AID1224758Delta TM value showing the stabilisation of CDK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224754Delta TM value showing the stabilisation of CAMK2G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1326307Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC BAA-41 after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID325541Inhibition of PKC2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224751Delta TM value showing the stabilisation of CAMK2A produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID314588Antagonist activity at LuxP receptor in Vibrio harveyi MM32 assessed as inhibition of autoinducer-2-mediated quorum sensing after 3 to 4 hrs2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi.
AID1224795Delta TM value showing the stabilisation of SLK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224759Delta TM value showing the stabilisation of CDKL1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224804Delta TM value showing the stabilisation of VRK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID294445Inhibition of xanthine oxidase2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Relationship between quantum-chemical descriptors of proton dissociation and experimental acidity constants of various hydroxylated coumarins. Identification of the biologically active species for xanthine oxidase inhibition.
AID1224805Delta TM value showing the stabilisation of VRK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224794Delta TM value showing the stabilisation of RSK2b produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224767Delta TM value showing the stabilisation of DAPK3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID403341Inhibition of COX12005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1224778Delta TM value showing the stabilisation of NEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1326306Antibacterial activity against Escherichia coli ATCC 25922 after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1224802Delta TM value showing the stabilisation of TNIK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1224793Delta TM value showing the stabilisation of RSK2a produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1326319Antibacterial activity against Klebsiella pneumoniae ATCC BAA-1144 after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1349252Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in A549 cells assessed as reduction in viral titer after 24 to 48 hrs by hemagglutination test2017Journal of natural products, 12-22, Volume: 80, Issue:12
Regioselective IBX-Mediated Synthesis of Coumarin Derivatives with Antioxidant and Anti-influenza Activities.
AID1224779Delta TM value showing the stabilisation of NEK6 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224775Delta TM value showing the stabilisation of ERK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID314590Growth inhibition of Vibrio harveyi assessed as time required to double bacterial growth relative to control2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Pyrogallol and its analogs can antagonize bacterial quorum sensing in Vibrio harveyi.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224800Delta TM value showing the stabilisation of MST4 (2) produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224782Delta TM value showing the stabilisation of PAK5 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224771Delta TM value showing the stabilisation of MEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224761Delta TM value showing the stabilisation of CLK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1244055Cytotoxicity against human U937 cells assessed as decrease in cell viability after 48 hrs2015European journal of medicinal chemistry, Aug-28, Volume: 101Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
AID1224796Delta TM value showing the stabilisation of LOK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224781Delta TM value showing the stabilisation of PAK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224773Delta TM value showing the stabilisation of ASK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224769Delta TM value showing the stabilisation of GSK3B produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224753Delta TM value showing the stabilisation of CAMK2D produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787Delta TM value showing the stabilisation of PIM2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325539Inhibition of EGFR2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224768Delta TM value showing the stabilisation of DMPK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224750Delta TM value showing the stabilisation of CAMK1G produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224762Delta TM value showing the stabilisation of CLK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1224797Delta TM value showing the stabilisation of MPSK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1326312Inhibition of Escherichia coli FtsZ GTPase activity expressed in Escherichia coli BL21 preincubated for 5 mins followed by GTP addition after 15 mins by malachite green based spectrophotometric analysis2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1224798Delta TM value showing the stabilisation of DRAK1 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1326320Antibacterial activity against methicillin-sensitive Staphylococcus aureus after 18 hrs by broth microdilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.
AID1224760Delta TM value showing the stabilisation of CHEK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224788Delta TM value showing the stabilisation of PIM3 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224792Delta TM value showing the stabilisation of RIOK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224748Delta TM value showing the stabilisation of AMPKA2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224756Delta TM value showing the stabilisation of CAMKK2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224803Delta TM value showing the stabilisation of PBK produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224765Delta TM value showing the stabilisation of CK1G2 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224755Delta TM value showing the stabilisation of CAMK4 produced by compound binding2007Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (159)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (3.14)18.7374
1990's6 (3.77)18.2507
2000's25 (15.72)29.6817
2010's72 (45.28)24.3611
2020's51 (32.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.79 (24.57)
Research Supply Index5.08 (2.92)
Research Growth Index5.30 (4.65)
Search Engine Demand Index76.22 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (3.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other154 (96.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]